Pfizer to spend $60M on UK stem cell unit
Global pharmaceuticals leviathan Pfizer has announced the launch of a new unit for stem cell science on a research center in Cambridge, UK, to be known as Pfizer Regenerative Medicine, which will involve an investment of some $60.0 million. The drugs giant will also set up a similar facility in Massachusetts, USA, which will bring the overall spend in this area of research to around $100.0 million.
This independent research unit will build on recent scientific progress in understanding the biology of stem cells and the opportunity that it provides, to discover and develop a new generation of regenerative medicines for major medical needs. The new unit will announce several significant scientific collaborations in the coming weeks "that will place Pfizer at the forefront of an emerging area of science that could one day bring hope and benefit to millions of patients worldwide," the firm pointed out in a statement.
Boost for UK stem cell science
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze